| Project/Area Number |
15K10343
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
SASAKI HIKARU 慶應義塾大学, 医学部(信濃町), 講師 (70245512)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
廣瀬 雄一 藤田保健衛生大学, 医学部, 教授 (60218849)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YOSHIDA Kazunari 慶應義塾大学, 医学部, 教授 (70166940)
SAYA Hideyuki 慶應義塾大学, 医学部, 教授 (80264282)
OHARA Kentaro 慶應義塾大学, 医学部, 助教 (40571724)
|
|---|
| Research Collaborator |
KITAMURA Yohei 済生会宇都宮病院, 脳神経外科
HAYASHI Saeko 慶應義塾大学, 医学部大学院
NAKAGAWA Yu 慶應義塾大学, 医学部大学院
KAMAMOTO Dai 慶應義塾大学, 医学部大学院
KANAZAWA Tokunori 慶應義塾大学, 医学部大学院
PAREIRA Eriel Sandika 慶應義塾大学, 医学部大学院
TSUZAKI Naoko , 実験助手
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | glioma / 1p/19q codeletion / MGMT / neoadjuvant / chemotherapy / personalized treatment / RGNT / molecular classification / Glioma / neoadjuvant chemotherapy / image / 1p/19q / 神経膠腫 / 画像 / 1p19q |
|---|
| Outline of Final Research Achievements |
The majority of diffuse gliomas is not curable yet, and the development of the personalized treatments according to molecular characteristics is indispensable. The main aims of this study were to establish the personalized therapies and to explore the utility of the neoadjuvant chemotherapy for chemo-sensitive gliomas. The prospective study for the diffuse gliomas with 1p/19q codeletion or MGMT promoter methylation suggested that upfront chemotherapy and subsequent resection for initial incomplete resections might be superior to chemotherapy and observation strategy. To preoperatively design the neoadjuvant strategy, we established the scoring systems to predict 1p/19q codeletion and MGMT methylation based on imaging features. Moreover, we have elucidated the molecular background of the rosette-forming glioneuronal tumor, molecular-pathological prognostic factors in 1p/19q-codeleted gliomas, and the factors favorably associated with long-term survival in glioblastoma patients.
|
